Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemed exceeds earnings expectations, focuses on strategic growth initiatives

Chemed's strong financial performance in 2022 was supported by targeted hiring and retention efforts.
Both VITAS and Roto-Rooter are focusing on improving staffing and revenue growth.
Chemed's strategic initiatives position the company well for future growth and operational efficiency.
The company's emphasis on culture and strategic approaches enhances valuation in the M&A market.

Chemed reports strong Q1 performance, optimistic about growth trajectory

Chemed's Q1 2023 earnings call highlighted a positive performance trajectory post-pandemic, with a focus on VITAS' growth and operational strategies. The company addressed challenges related to Medicare reimbursement rates and emphasized opportunities for further expansion and staff satisfaction.

Chemed's VITAS shines, Roto-Rooter adapts to consumer challenges

Chemed's Q2 2023 earnings call highlighted VITAS' strong performance and operational improvements post-pandemic.
Roto-Rooter faced challenges in consumer spending but focused on enhancing online presence and conversion rates.
Both segments showcased resilience amidst economic headwinds, with strategic initiatives in place to drive growth and operational efficiency.
Chemed's strategic cost management and revenue generation strategies position the company for sustainable growth and margin protection.

Chemed reports strong Q3 performance, eyes growth amid economic challenges

Chemed's diversified business segments showed resilience and growth potential, with VITAS Healthcare and Roto-Rooter both demonstrating strengths and addressing challenges. The company remains cautiously optimistic about 2024, focusing on operational efficiency and market dynamics for sustained performance.

Chemed's VITAS shines in Q4 with strong growth, Roto-Rooter faces challenges

Chemed's VITAS segment excelled with strong revenue growth and operational improvements, while Roto-Rooter faced challenges in call volume.
Management's confidence in sustained growth and margin improvement presents opportunities for both VITAS and Roto-Rooter in 2024.
Strategies to address challenges and capitalize on opportunities will be crucial for Chemed's divisions to meet their forecasted targets.
Overall, Chemed's performance in Q4 2023 sets a positive tone for the company's outlook and strategic initiatives moving forward.

Chemed excels in hospice segment, Roto-Rooter faces commercial challenges

Chemed's VITAS segment outperformed, while Roto-Rooter faced challenges, prompting strategic actions to enhance commercial performance and drive growth.

Chemed's VITAS shines in Q2 2024, Roto-Rooter faces revenue challenges

Chemed's VITAS segment is driving revenue growth and margin expansion, while Roto-Rooter faces challenges in revenue decline. The company aims to capitalize on growth opportunities in the hospice services sector.

Chemed's VITAS shines amid Roto-Rooter's challenges in Q3 2024

Chemed's earnings call showcased VITAS' resilience and growth prospects, while addressing Roto-Rooter's challenges and strategic adjustments. The company remains optimistic about adjusted net income outlook for the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Is  (CHE) Outperforming Other Medical Stocks This Year?

Is Chemed (CHE) Outperforming Other Medical Stocks This Year?

Chemed (CHE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Chemed (CHE) Might Surprise This Earnings Season

Cigna

CURO Group Hlds

Huron Consulting Group

Limelight Networks

Five growth stocks with a favorable Zacks Rank that are set to beat first-quarter earnings estimates this month.

5 Top Growth Stocks to Buy Ahead of Q1 Earnings This Month

Chemed (CHE) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Chemed (CHE) Is a Great Growth Stock

Enphase Energy

Leidos Hld

After the recent market swoon, these stocks offer powerful upsides.

3 Top Mid - Cap Stocks to Buy Right Now

AMN Healthcare Services

Humana

Earnings results of healthcare sector are likely to reflect solid demand for its products and services from aging population and the growing incidence of COVID-19 illness.

5 Healthcare Stocks Poised to Beat Earnings Estimates in Q1

DexCom

Eli Lilly

SAGE Therapeutics

ViewRay

Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.

Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results

Costco

CoStar Group

Lockheed Martin

NextEra Energy

NVIDIA

Shopify

Given coronavirus volatility in the market, the smartest move for investors right now is to buy quality, not hype. That's good advice at any time.

7 A-Rated Stocks to Buy For Portfolio Strength In Uncertain Times

Amedisys

Atmos Energy

AeroVironment

To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.

Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts

Cardinal Health

Dropbox

Royal Philips

Although the death toll continues to go up in the United States, the curves related to hospitalization, intensive-care check-ins and intubations are gradually flattening.

U.S. Economy Likely to Reopen in May: 5 Top Growth Picks

Chemed (CHE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Chemed (CHE)

Chemed (CHE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chemed (CHE) Upgraded to Strong Buy: What Does It Mean for the Stock?

A10 Networks

Core-Mark Holding Company

Masimo

The S&P 500's average daily percentage price change over the past five weeks has been plus or minus 4.8%. This explains why the Cboe Volatility Index remains elevated at around the 40s.

5 Low-Risk Stocks to Buy for Epic Price Swings Since 1929

Tradeweb Markets

Although, short-term fluctuations will continue on account of the coronavirus-induced crisis, overall market movement will remain positively sloped.

Market to Stay Northbound Despite Volatility:  5 Growth Picks

FormFactor

Tandem Diabetes Care

This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.

Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off

Chemed (CHE) reported earnings 30 days ago. What's next for the stock?

Why Is Chemed (CHE) Down 28.5% Since Last Earnings Report?

CVS Health

LHC Group

The COVID-19 outbreak has pushed shares of at least three terrific businesses down to bargain prices.

3 Top Healthcare Stocks to Buy on the COVID-19 Dip

Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Chemed (CHE) is an Incredible Growth Stock: 3 Reasons Why

Chemed (CHE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Chemed (CHE) Stock Stands Out in a Strong Industry

AAR CORP.

BMC Stock Hlds

JetBlue Airways

Gibraltar Industries

Since a debt-free company is rare to find, measuring the debt level of a company is an important point of consideration while making an investment decision.

Risk-Averse Investors May Buy These 5 Low Leverage Stocks

Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy Chemed (CHE) Now

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Chemed (CHE) Upgraded to Strong Buy: Here's Why

Chemed Corporation (CHE) CEO Kevin McNamara on Q4 2019 Results - Earnings Call Transcript

Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.

Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up

Bank of Montreal

Ralph Lauren

Teradyne

Exorbitant debt financing might lead to a corporation's bankruptcy in the worst-case scenario. Since a debt-free company is rare to find, we should focus on those carrying low debt levels

News for Chemed Stock (CHE)